Changsha, China – New research published in Arthritis & Rheumatology suggests that for people overweight or with obesity who also have knee or hip osteoarthritis, a slow-to-moderate—but not fast—rate of weight loss caused by anti-obesity medications may lower their risk of premature death. Among 6,524 participants with knee or hip...
Latest News
San Francisco, Calif. – A team of international research institutions, led by UC San Francisco, has completed the first large-scale study of posterior cortical atrophy, a baffling constellation of visuospatial symptoms that present as the first symptoms of Alzheimer’s disease. These symptoms occur in up to 10% of cases of...
Neurological diseases including Parkinson’s, Tourette’s, attention deficit hyperactivity disorder (ADHD), Alzheimer’s, and schizophrenia are all associated with alterations in dopamine-driven function involving the dopamine transporter (DAT). Research published today in the open access journal BMC Neuroscience suggests that a number of estrogens acting through their receptors affect the DAT, which...
Boston, Mass. – In the early 1990s, Mike McCune and his colleagues thought they’d found a path to a one-time HIV treatment for babies: genetically modifying hematopoietic stem cells to suppress the virus and then transplanting them into the bone marrow. But the treatment never made it to clinical trials....
CAMBRIDGE, Mass. — Count Me In, a patient-partnered research initiative led by the Broad Institute of MIT and Harvard and Dana-Farber Cancer Institute, is launching a new project focused on translocation renal cell carcinoma (tRCC), a rare and aggressive form of kidney cancer. The effort will engage with tRCC patients,...
A Lakewood family will bike in the 20th annual Children’s Hospital Courage Classic to help raise money for the medical center that has treated their son since birth. Stefan and Brenda Van der Steen will take part in the 3-day tour, which passes through Copper Mountain and Leadville for three...
CHICAGO, Ill. — COUR Pharma, a clinical-stage biotechnology company developing first-in-class, antigen-specific immune tolerance therapies for autoimmune diseases, announced today the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to CNP-106, an investigational therapy for the treatment of generalized myasthenia gravis (gMG). CNP-106 is a biodegradable...
Kuopio, Finland – A new study identifies alterations in the transcriptomic signatures in human olfactory mucosal cells of individuals with Alzheimer’s disease following SARS-CoV-2 infection, potentially contributing to exacerbated COVID-19 outcomes. The study was conducted at the University of Eastern Finland in collaboration with the University of Helsinki and published...
HOUSTON, TX — Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, announces that the U.S. Food and Drug Administration (“FDA” or the “Agency”) has accepted its Investigational New Drug (IND) application for...
HOUSTON, Texas — Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, announced today the launch of the ALSTARS Trial, a Phase 2, randomized, multi-center, double-blind, placebo-controlled study to evaluate the...